OCUL.NASDAQOcular Therapeutix, INC

Form 4: OCUL Executive Transfers Shares to Spouse

Sentiment:

Insider Transaction Report

📋All filings for Ocular Therapeutix, INC
🔒Login to Follow

Ocular Therapeutix's Executive Chairman, President, and CEO, Pravin Dugel, transferred 49,754 shares of common stock to his spouse as a gift.

Summary

  • Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, Inc. (OCUL), reported a change in beneficial ownership.
  • On September 9, 2025, Mr. Dugel transferred 49,754 shares of common stock to his spouse.
  • The transfer was a gift, with no consideration exchanged ($0 price).
  • Following the transaction, Mr. Dugel directly owns 3,177,490 shares.
  • His spouse indirectly owns 49,754 shares, and the Pravin Dugel 2024 Irrevocable Trust indirectly owns 250,361 shares.

Sentiment

Score: 5

Explanation: The transaction is a routine insider gift transfer for personal financial planning purposes, which is neutral for the company's operational performance or strategic direction.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This insider transaction is a personal financial planning event for an executive and does not directly relate to broader industry trends or competitive landscape.

Related Party Transactions

  • Transfer of 49,754 shares of common stock from Pravin Dugel to his spouse for no consideration.

Stakeholder Impact

  • Shareholders: Minimal direct impact as it is a transfer within the executive's family, not a sale to the open market. The total shares outstanding remain unchanged.
  • Management: Reflects personal financial planning by the Executive Chairman, President, and CEO.

Key Dates

DateDescription
09/09/2025Date of share transfer by Pravin Dugel to his spouse.
09/11/2025Date the Form 4 was signed by Todd Anderman, Attorney-in-Fact for Pravin Dugel.

Recommendation

hold

The filing details a routine insider gift transfer of shares to a spouse, which is a personal financial planning event and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation.

Keywords

Ocular Therapeutix, OCUL, Pravin Dugel, Insider Transaction, Form 4, Share Transfer, Beneficial Ownership, Executive Chairman, CEO, Common Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.